Molecule Activates DeSci Ecosystem Support: Allocating BIO to Pump Science Community
Molecule is excited to support pump.science with a BIO allocation for community growth initiatives. Through this BIO allocation, pump.science will explore ways to reward their early community members
2 min read
Jillian Casalini
TL;DR
- DeSci Ecosystem Activation: Molecule is allocating BIO tokens to support the pump.science community, backing their mission to advance community-backed research on Solana.
- Power of the BIO Token: BIO is the governance token for the Bio Protocol, granting holders access to diverse BioDAOs and scientific initiatives, empowering the community to shape research across fields like Long COVID and Quantum Biology.
Molecule is focused on accelerating scientific research and bringing intellectual property onchain through community-driven initiatives. This commitment underpins our support of pump.science, a crypto-powered research protocol where anyone can launch and fund research experiments. The pump.science community of PhDegens have shown that community-backed research on Solana is possible.
Molecule is excited to support pump.science with a BIO allocation for community growth initiatives. Through this BIO allocation, pump.science will explore ways to reward their early community members and create deeper connections within the broader BioDAO ecosystem. As the native governance token of the Bio Protocol, BIO empowers holders to participate in governance across a diverse range of BioDAOs and scientific IP assets. With a single token, users gain access to multiple areas of research and initiatives within the BIO ecosystem, making it the ultimate entry point into Bio’s DeSci community. What's Nextpump.science will be rolling out its first BIO-powered community initiatives soon. Keep an eye on their X or join their telegram for details.
About the author
Jillian Casalini
I'm a biotech strategist and marketer with a foundation in traditional pharma and a vision for decentralized innovation. My career began in traditional pharma at Eli Lilly, where I learned how large-scale organizations bring rigor, regulation, and reach to life sciences. I also built a strong foundation in go-to-market strategy—bridging science with storytelling and turning complex research into clear, compelling narratives. That experience now fuels my passion for building at the intersection of biotech and decentralized science (DeSci)—where transparency, open collaboration, and new funding models are reshaping how research gets done.
